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Summary The severity and extent of disease caused by multidrug-resistant
organisms (MDROs) varies by the population(s) affected and the institution(s) at
which these organisms are found; therefore, preventing and controlling MDROs are
extremely important.
A retrospective study of patients who were infected with Acinetobacter baumannii
or Pseudomonas aeruginosa was performed at the Spedali Civili Hospital in Brescia,
Italy, from 2007 to 2010.
A total of 167 (0.52%) A. baumannii isolates and 2797 P. aeruginosa (8.7%) isolates
were identiﬁed among 31,850 isolates.
Amikacin and colistin were the most active agents against A. baumannii strains.
Multidrug resistance (MDR) was observed in 57 isolates (54%). Most MDR isolates (42
out of 57, 73%) were resistant to four classes of antibiotics.
P. aeruginosa was recovered more frequently from the respiratory tract, followed
by the skin/soft tissue, urine and blood.
Colistin, amikacin and piperacillin/tazobactam were active against 100%, 86% and
75% of P. aeruginosa isolates, respectively. A total of 20% (n = 316) of P. aeruginosa
isolates were MDR. In summary, A. baumannii was more rare than P. aeruginosa but
was more commonly MDR.Epidemiological data will help to implement better infection control strategies,
and developing a local antibiogram database will improve the knowledge of antimi-
crobial resistance patterns in our region.
© 2013 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier
Ltd. All rights reserved.
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Introduction
Nosocomial infections are one of the most com-
mon complications of hospitalization and lead to
increased morbidity and mortality [1,2]. These
infections prolong hospitalization, require more
extensive diagnostics and treatment and are asso-
ciated with additional costs [3,4]. Infection with
multidrug-resistant pathogens can also complicate
treatment.
Antibiotic resistance is a daunting phe-
nomenon with a growing impact on patient
safety, particularly in ICUs [5]. Critically ill
patients are prone to colonization and infec-
tion by antibiotic-resistant bacteria because
of the frequent exposure of these patients
to antibiotics and the presence of multiple,
often invasive, devices. This dangerous array of
risk factors drives a vicious cycle of increased
infection incidence, increased need for broad-
spectrum antibiotics, reduced antimicrobial
efﬁcacy and increased selection of antibiotic
resistance.
Multidrug-resistant organisms (MDROs) are resis-
tant to one or more classes of antimicrobial agents,
such as -lactams (penicillins, cephalosporins,
monobactams and carbapenems), ﬂuoroquinolones
and aminoglycosides. During the past several
decades, a shift in the MDR dilemma from
gram-positive to gram-negative bacteria has been
noted, which is in part due to the small num-
ber of new antimicrobial agents that are active
against resistant gram-negative strains [6]. Gram-
negative pathogens that have acquired epidemi-
ological importance among nosocomial infections
include Acinetobacter baumannii and Pseudomonas
aeruginosa.
A. baumannii is a cause of outbreaks in hospi-
tals [7,8], and the MDR patterns observed among
isolates often leave carbapenems as the only
effective treatment for severe infections [8].
However, carbapenem-resistant A. baumannii is
emerging worldwide and has been observed in
different countries [7,9—11]. There are limited
therapeutic options for infections caused by these
isolates.
P. aeruginosa is also a common gram-negative
nosocomial pathogen. This organism is an impor-
tant cause of hospital-acquired pneumonia and
urinary tract, wound and bloodstream infections
[12]. Infections caused by this pathogen are often
difﬁcult to treat because of the multidrug-resistant
nature of this bacterial species, and P. aeruginosa
strains are often carbapenem resistant, which can
severely limit the available therapeutic choices
[13].
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The purposes of this study were the following:
a) to determine the prevalences of A. baumannii
and P. aeruginosa in patients with nosocomial
infections at Brescia’s main hospital; and
b) to analyze the antimicrobial susceptibility pat-
terns of these two microorganisms determined
as part of an internal laboratory surveillance
study from 2007 to 2010.
ethods
acterial isolates
retrospective study of all A. baumannii and P.
eruginosa isolates from different clinical spec-
mens collected from patients with nosocomial
nfections and processed by the microbiology lab-
ratory between 2007 and 2010 was conducted at
he Spedali Civili Hospital in Brescia, Italy. Spedali
ivili is a major hospital with an average of approx-
mately 47,000 hospitalizations annually. Infections
ere considered nosocomial if they ﬁrst appeared
8 h after admission. Infections that were likely to
ave been acquired before hospital admission were
ot considered nosocomial. Blood, urine, tracheal
spirate, bronchi alveolar lavage, sputum, puru-
ent wound, skin ulcer and catheter tip samples
ollected from patients admitted to all units (ICU
nd other departments) were eligible. Duplicate
solates were excluded.
Clinical specimens were plated onto blood agar
nd MacConkey agar and incubated overnight at
7 ◦C. After incubation for 24 h at 37 ◦C, the orga-
isms were identiﬁed using the VitekTM system
bioMerieux, Marcy-l’Etoile, France).
ntimicrobial susceptibility
ntimicrobial susceptibility was assessed using
he Vitek2 system (bioMerieux) and the AST-GN24
ard according to the manufacturer’s instruc-
ions. The results obtained after a maximum
f 15 h of incubation were analyzed and inter-
reted by AES 4.02 software. The MICs determined
y the system identiﬁed the microorganism as
usceptible, intermediate or resistant accord-
ng to the criteria published by the CLSI [14].
ntibiotic resistance was categorized into ﬁve
roups: (1) resistance to extended-spectrum peni-
illins (piperacillin/tazobactam), (2) resistance to
ephalosporins (ceftazidime), (3) resistance to car-
apenems (imipenem), (4) resistance to aminogly-
osides (amikacin) and (5) resistance to quinolones
ciproﬂoxacin). The breakpoints for these antimi-
robials were as follows: amikacin, S≤ 16 and
≥ 32; ceftazidime, S≤ 8 and R≥ 16; imipenem,
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Table 1 Prevalence of A. baumannii strains obtained during the study period and their distributions in different
clinical samples.
A. baumannii
2007 2008 2009 2010
Total = 23a Total = 21 Total = 48 Total = 75
No. of infections/colonizationsb
21 17 36 46
A. baumannii
No (%) No (%) No (%) No (%)
Type of infected/colonized specimen
Respiratory tract 8 (38) 6 (35.3) 18 (50) 24 (52.2)
Skin/soft tissue 7 (33.3) 7 (41.2) 10 (27.8) 15 (32.6)
Blood 1 (4.8) 3 (17.6) 4 (11.1) 0
Urine 3 (14.3) 0 2 (5.5) 3 (6.5)
Other clinical specimens 2 (9.6) 1 (5.9) 2 (5.5) 4 (8.7)
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(a Total strains, including duplicates.
b All clinical specimens positive for A. baumannii;.
≤ 4 and R≥ 16; ciproﬂoxacin, S≤ 1 and R≥ 4
all for both strains); and piperacillin/tazobactam,
≤ 16/4 and R≥ 64/4 for A. baumannii strains
nd S≤ 64/4 and R≥ 128/4 for P. aeruginosa
trains. Colistin susceptibility was tested using the
irby—Bauer disk diffusion with 10g colistin disks
OXOID S.p.A., Milan, Italy). The inhibition zone
iameters were interpreted according to the CLSI
uidelines for colistin (resistant≤ 10mm and sus-
eptible≥ 11mm). The strains were deﬁned as R0
absence of resistance to all ﬁve classes of antibi-
tics), R1 (resistant to one class of antibiotics), R2
resistant to two classes of antibiotics), R3 (resis-
ant to three classes of antibiotics), R4 (resistant to
our classes of antibiotics) and R5 (resistant to ﬁve
lasses of antibiotics).
In agreement with previous reports, the term
‘multidrug resistance’’ was used to describe resis-
ance to three or more classes of antimicrobial
gents [15,16].
tatistical analysis
he Fisher exact test and the chi-square test for
inear trend analysis were used to evaluate both
he differences in the distributions of the isolates
nd the trend in the susceptibility rate. A p value
f <0.05 was considered signiﬁcant.
esults. baumannii
mong the 31,850 isolates collected from hospi-
alized patients over the 4-year study period, 167
n
H
p
t0.52%) were identiﬁed as A. baumannii. Specimens
ere collected from the respiratory tract (46.6%;
= 56), skin/soft tissue (32.5%; n = 39), blood (6.6%;
= 8), urine (6.6%; n = 8) and other locations (7.5%;
= 9) (Table 1). Increases in the percentages of
trains isolated from the respiratory tract and
kin/soft tissue were observed in 2009 and 2010.
More A. baumannii isolates than P. aeruginosa
solates were resistant to the tested antibiotics
Table 2). The percentage of susceptible A. bau-
annii strains was 82% for amikacin, approximately
0% for imipenem and piperacillin/tazobactam and
6% for ceftazidime and ciproﬂoxacin. All strains
ere susceptible to colistin. Fifty-seven isolates
54%) were MDR (Table 3). Three isolates were resis-
ant to three classes of antibiotics, and most MDR
solates (42 out of 57, 73%) were resistant to four
lasses of antibiotics. Eleven isolates were resistant
o all ﬁve classes of antimicrobials. A signiﬁcant
ncrease (p < 0.05) in the percentage of R5 isolates
as observed in 2010.
. aeruginosa
. aeruginosa was identiﬁed in 2797 isolates (8.8%)
f the 31,850 isolates collected from hospital-
zed patients during the study period. Like A.
aumannii, most P. aeruginosa strains were recov-
red from the respiratory tract (42.8%; n = 790),
ollowed by skin/soft tissue (26%; n = 480), urine
13.5%; n = 349), other clinical specimens (11%;
= 204) and blood cultures (6.5%; n = 121) (Table 4).
owever, a signiﬁcant decrease (p < 0.01) in the
ercentage of P. aeruginosa strains isolated from
he respiratory tract over time was observed;
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Table 2 Antimicrobial susceptibility patterns of 167 A. baumannii and 2797 P. aeruginosa strains collected from
2007 to 2010.
Antimicrobial agents A. baumannii P. aeruginosa
CLSI breakpoint interpretation CLSI breakpoint interpretation
%S %I %R %S %I %R
Amikacin 82 0 18 86 0 14
Ceftazidime 16 0 84 69 0 31
Ciproﬂoxacin 16 0 84 58 0 42
Imipenem 24 0 76 64 0 36
Piperacillin/tazobactam 19 0 81 75 0 25
%S = percent susceptible; %I = percent intermediate; %R = percent resistant.
Table 3 Trends in the antimicrobial resistance patterns of A. baumannii isolates tested from 2007 to 2010.
2007 2008 2009 2010
n = 21 n = 17 n = 31 n = 36
R0 11 (52.4) 8 (47) 11 (35.5) 10 (27.8)
R1 1 (4.8) 2 (11.8) 1 (3.2) 1 (2.8)
R2 0 1 (5.9) 1 (3.2) 1 (2.8)
R3a 0 0 2 (6.5) 1 (2.8)
R4a 9 (42.8) 5 (29.4) 15 (48.4) 14 (38.8)
R5a 0 1 (5.9) 1 (3.2) 9 (25)*
a Multidrug-resistant isolates.
* p < 0.05.
** p < 0.01.
Table 4 Prevalence of P. aeruginosa strains obtained during the study period and their distribution in different
clinical samples.
P. aeruginosa
2007 2008 2009 2010
Total = 575a Total = 732 Total = 798 Total = 692
No. of infections/colonizationsb
362 482 534 466
P. aeruginosa
No (%) No (%) No (%) No (%)
Type of infected/colonized specimen
Respiratory tract 198 (54.7) 197 (41)** 216 (40)** 179 (38)**
Skin/soft tissue 79 (21.8) 154 (32)** 133 (25) 114 (24.5)
Blood 14 (3.9) 32 (6.6) 44 (8.2)** 31 (6.6)
Urine 65 (18) 52 (11)** 71 (13.3) 61 (13.1)
Other clinical specimens 6 (1.6) 47(9.7)** 70 (13)** 81 (17)**
a Total strains, including duplicates.
b All clinical specimens positive for P. aeruginosa.
* p < 0.05.
** p < 0.01.
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Table 5 Trends in the antimicrobial resistance patterns of Pseudomonas aeruginosa isolates tested from 2007 to
2010.
2007 2008 2009 2010
n = 328 n = 402 n = 452 n = 392
R0 141 (43) 179 (44.5) 214 (47.3) 163 (41.6)
R1 63 (19.2) 87 (21.7) 82 (18.1) 89 (22.7)
R2 60 (18.3) 62 (15.4) 69 (15.3) 49 (12.5)
R3a 31 (9.5) 29 (7.2) 23 (5.1)* 42 (10.7)**
R4a 26 (7.9) 37 (9.2) 49 (10.8) 33 (8.4)
R5a 7 (2.1) 8 (2) 15 (3.4) 16 (4.1)
a Multidrug-resistant isolates.
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n contrast, a signiﬁcant increase was observed
n the recovery of P. aeruginosa from different
linical specimens (p < 0.01). Colistin (100% suscep-
ible), amikacin (85%) and piperacillin/tazobactam
75%) had the highest susceptibility rates among
he antimicrobial agents tested. The susceptibility
ates for carbapenems and cephalosporins ranged
rom 64% for imipenem to 69% for ceftazidime.
ower activity was observed for ciproﬂoxacin
58%).
Of the 1574 isolates from infected/colonized
atients, 20% (n = 316) were MDR (Table 5). Most
solates were resistant to four classes of antibi-
tics (145 out of 316, 45.8%), followed by three
lasses of antibiotics (125 out of 316, 39.5%) and
ll ﬁve classes of antimicrobial agents (46 out of
16, 14.5%).
A signiﬁcant decrease (p < 0.05) in the percent-
ge of R3 strains was observed from 2007 to 2009,
ollowed by a signiﬁcant increase (p < 0.01) from
009 to 2010.
iscussion
he data collected as part of an internal labora-
ory surveillance program were used in the present
tudy to draw conclusions about the occurrence of
pidemiologically important pathogens responsible
or nosocomial infections. Despite the increased
ates of A. baumannii infection reported world-
ide and the ﬁndings of the clonal expansion of
hese microorganisms in clinical settings, particu-
arly ICUs [7,8,17], A. baumannii represented only
.52% of all organisms isolated over the 4-year study
eriod.
The most serious current problem regarding the
reatment of Acinetobacter infections is acquired
DR, resulting in the availability of few effective
ntimicrobial agents. MDR can be to the result of
[
p
ahe presence of a single resistance determinant
hat confers resistance to more than one class of
ntimicrobial agent, such as MDR pumps. MDR can
lso be due to the presence of multiple resistance
eterminants [18]. Some strains of A. bauman-
ii that are resistant to all antibiotics have been
etected [19,20]. A surveillance study in Korea
n 2009 [21] showed that the resistance rates of
cinetobacter were very high: 67% of isolates were
esistant to ﬂuoroquinolones, 48% to amikacin, 66%
o ceftazidime and 51% to imipenem. This resis-
ance trend was largely similar to that observed in a
tudy conducted by The Surveillance Network (TSN)
n the U.S. [22]. In our study, we observed more fre-
uent resistance to imipenem (80%), ceftazidime
nd ciproﬂoxacin (84%), whereas resistance to
mikacin was less frequent (18%). Fifty-seven iso-
ates (54%) were MDR, with an increase in the
ercentage of strains resistant to all ﬁve classes of
ntibiotics.
Nosocomial strains of P. aeruginosa are fre-
uently resistant to a broad range of antibiotics.
he prevalence of nosocomial strains of P.
eruginosa appears to be increasing worldwide,
specially as a cause of ventilator-associated
neumonia; their prevalence in high-risk popu-
ations, such as patients with severe burn
njuries, is also increasing [23]. Pseudomonas
s most commonly isolated from the respira-
ory tract, followed by wounds, urine and blood
19]. This ﬁnding is in agreement with our
esults. Pseudomonas is intrinsically resistant to
ost antibiotics. Antimicrobial resistance develops
nder selective pressure, and multiple mecha-
isms are responsible: the (hyper-) production of
nzymes, such as beta-lactamases and DNA gyrases;
ctive efﬂux pumps; and permeability changes
19].Our results show that colistin, amikacin and
iperacillin/tazobactam were the most active
ntipseudomonal antimicrobials evaluated, a result
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that is corroborated by the ﬁndings of other
studies [12]. Additionally, the limited activity of
ciproﬂoxacin could be due to the overuse of this
antimicrobial agent in clinical settings. In this study,
we found that 316 strains (20%) were MDR. The
majority of isolates were resistant to four classes
of antibiotics (145 out of 316, 45.8%). Among MDR
P. aeruginosa isolates, colistin showed good activ-
ity and could therefore be a useful alternative
treatment; however, this agent is has considerable
toxicity [15,24].
The ongoing surveillance of these microorgan-
isms is important to help direct antimicrobial
therapy and monitor the emergence of potentially
drug-resistant strains in Brescia, Italy.
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